New method may halt Alzheimer's disease

Researchers have discovered a new method that may halt the progression of dementia caused by accumulation of a protein known as tau.

Normally, tau protein is involved in microtubule formation, which acts as a brain cell's transportation system for carrying nutrients in and waste out.

In the absence of tau protein, brain cells become dysfunctional and eventually die, said researchers at the University of Texas Medical Branch at Galveston.

In many forms of dementia, such as Alzheimer's disease and chronic traumatic encephalopathy caused by multiple concussions, the tau protein starts behaving badly and instead of performing its normal cellular functions, it begins accumulating and interfering with cell-to-cell communications.

Without the ability of brain cells to receive signals, they become severely dysfunctional and if enough of them die in a given area of the brain, the result is cognitive impairment, which means difficulty in planning tasks and remembering things.

This accumulation of tau results in the formation of tau oligomers, the toxic form of tau protein.

Scientists believe that if you can get rid of this toxic oligomeric tau protein, you can potentially stop the spread of tau-related dementia.

The trick is to remove the toxic oligomeric tau without also removing the normal, functional tau protein.

Researchers did just that and demonstrated that treatment with their tau oligomer-specific monoclonal antibody, called TOMA, in experiments involving a rodent model of tauopathy (tau-related dementia) improved locomotor function and performance on memory tests.

The TOMA antibody sticks to the oligomeric tau so it can no longer interfere with cell-to-cell communication, but leaves the native tau protein intact.

"This is significant because this research describes a very promising vaccination strategy for Alzheimer's disease, which could prevent memory loss from occurring later in life," said professor Rakez Kayed, senior author of the study.

"No safety concerns were detected in mice receiving this treatment, but more research is needed to confirm the efficacy and safety of immunisation in other animals and in humans," said Kayed.

The study was published in the Journal of Neuroscience.

image
Business Standard
177 22
Business Standard

New method may halt Alzheimer's disease

Press Trust of India  |  Washington 



Researchers have discovered a new method that may halt the progression of dementia caused by accumulation of a protein known as tau.

Normally, tau protein is involved in microtubule formation, which acts as a brain cell's transportation system for carrying nutrients in and waste out.



In the absence of tau protein, brain cells become dysfunctional and eventually die, said researchers at the University of Texas Medical Branch at Galveston.

In many forms of dementia, such as Alzheimer's disease and chronic traumatic encephalopathy caused by multiple concussions, the tau protein starts behaving badly and instead of performing its normal cellular functions, it begins accumulating and interfering with cell-to-cell communications.

Without the ability of brain cells to receive signals, they become severely dysfunctional and if enough of them die in a given area of the brain, the result is cognitive impairment, which means difficulty in planning tasks and remembering things.

This accumulation of tau results in the formation of tau oligomers, the toxic form of tau protein.

Scientists believe that if you can get rid of this toxic oligomeric tau protein, you can potentially stop the spread of tau-related dementia.

The trick is to remove the toxic oligomeric tau without also removing the normal, functional tau protein.

Researchers did just that and demonstrated that treatment with their tau oligomer-specific monoclonal antibody, called TOMA, in experiments involving a rodent model of tauopathy (tau-related dementia) improved locomotor function and performance on memory tests.

The TOMA antibody sticks to the oligomeric tau so it can no longer interfere with cell-to-cell communication, but leaves the native tau protein intact.

"This is significant because this research describes a very promising vaccination strategy for Alzheimer's disease, which could prevent memory loss from occurring later in life," said professor Rakez Kayed, senior author of the study.

"No safety concerns were detected in mice receiving this treatment, but more research is needed to confirm the efficacy and safety of immunisation in other animals and in humans," said Kayed.

The study was published in the Journal of Neuroscience.

RECOMMENDED FOR YOU

New method may halt Alzheimer's disease

Researchers have discovered a new method that may halt the progression of dementia caused by accumulation of a protein known as tau. Normally, tau protein is involved in microtubule formation, which acts as a brain cell's transportation system for carrying nutrients in and waste out. In the absence of tau protein, brain cells become dysfunctional and eventually die, said researchers at the University of Texas Medical Branch at Galveston. In many forms of dementia, such as Alzheimer's disease and chronic traumatic encephalopathy caused by multiple concussions, the tau protein starts behaving badly and instead of performing its normal cellular functions, it begins accumulating and interfering with cell-to-cell communications. Without the ability of brain cells to receive signals, they become severely dysfunctional and if enough of them die in a given area of the brain, the result is cognitive impairment, which means difficulty in planning tasks and remembering things. This ... Researchers have discovered a new method that may halt the progression of dementia caused by accumulation of a protein known as tau.

Normally, tau protein is involved in microtubule formation, which acts as a brain cell's transportation system for carrying nutrients in and waste out.

In the absence of tau protein, brain cells become dysfunctional and eventually die, said researchers at the University of Texas Medical Branch at Galveston.

In many forms of dementia, such as Alzheimer's disease and chronic traumatic encephalopathy caused by multiple concussions, the tau protein starts behaving badly and instead of performing its normal cellular functions, it begins accumulating and interfering with cell-to-cell communications.

Without the ability of brain cells to receive signals, they become severely dysfunctional and if enough of them die in a given area of the brain, the result is cognitive impairment, which means difficulty in planning tasks and remembering things.

This accumulation of tau results in the formation of tau oligomers, the toxic form of tau protein.

Scientists believe that if you can get rid of this toxic oligomeric tau protein, you can potentially stop the spread of tau-related dementia.

The trick is to remove the toxic oligomeric tau without also removing the normal, functional tau protein.

Researchers did just that and demonstrated that treatment with their tau oligomer-specific monoclonal antibody, called TOMA, in experiments involving a rodent model of tauopathy (tau-related dementia) improved locomotor function and performance on memory tests.

The TOMA antibody sticks to the oligomeric tau so it can no longer interfere with cell-to-cell communication, but leaves the native tau protein intact.

"This is significant because this research describes a very promising vaccination strategy for Alzheimer's disease, which could prevent memory loss from occurring later in life," said professor Rakez Kayed, senior author of the study.

"No safety concerns were detected in mice receiving this treatment, but more research is needed to confirm the efficacy and safety of immunisation in other animals and in humans," said Kayed.

The study was published in the Journal of Neuroscience.
image
Business Standard
177 22
Widgets Magazine

More News

Widgets Magazine
Widgets Magazine

Upgrade To Premium Services

Welcome User

Business Standard is happy to inform you of the launch of "Business Standard Premium Services"

As a premium subscriber you get an across device unfettered access to a range of services which include:

  • Access Exclusive content - articles, features & opinion pieces
  • Weekly Industry/Genre specific newsletters - Choose multiple industries/genres
  • Access to 17 plus years of content archives
  • Set Stock price alerts for your portfolio and watch list and get them delivered to your e-mail box
  • End of day news alerts on 5 companies (via email)
  • NEW: Get seamless access to WSJ.com at a great price. No additional sign-up required.
 

Premium Services

In Partnership with

 

Dear Guest,

 

Welcome to the premium services of Business Standard brought to you courtesy FIS.
Kindly visit the Manage my subscription page to discover the benefits of this programme.

Enjoy Reading!
Team Business Standard